Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pumitamig + sacituzumab govitecan
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pumitamig + sacituzumab govitecan is an investigational combination regimen consisting of pumitamig (BNT327/BMS-986545), a bispecific antibody targeting programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A), and sacituzumab govitecan (Trodelvy), a TROP2-directed antibody-drug conjugate (ADC). The combination is being developed under a clinical trial collaboration and supply agreement between BioNTech and Gilead Sciences. It is being evaluated as a first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer (TNBC) in the global Phase 3 ROSETTA Breast-01 trial (NCT07173751), where it is planned to replace the chemotherapy component of the trial's original pumitamig-plus-chemotherapy regimen.
- Other names
- BNT327 + sacituzumab govitecanBNT327 + sacituzumab govitecan-hziyBNT327 + Trodelvypumitamig + sacituzumab govitecan-hziypumitamig + Trodelvypumitamig and sacituzumab govitecanpumitamig and Trodelvy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)TACSTD2 (Tumor-associated calcium signal transducer 2)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on pumitamig + sacituzumab govitecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pumitamig + sacituzumab govitecan.